Skip to main content
Annexon, Inc. logo

Annexon, Inc. — Investor Relations & Filings

Ticker · ANNX ISIN · US03589W1027 US Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2021-07-22 Regulatory Filings
Country US United States of America
Listing US ANNX

About Annexon, Inc.

https://annexonbio.com/

Annexon, Inc. is a clinical-stage biopharmaceutical company developing a new class of complement medicines. The company's therapeutic approach is centered on inhibiting C1q, the initiating molecule of the classical complement pathway. By blocking C1q at the start of this immune cascade, Annexon aims to prevent the inflammation and tissue damage that drive a range of diseases. Its pipeline is focused on developing treatments for classical complement-mediated disorders affecting the body, brain, and eye, which include autoimmune, neurodegenerative, and ophthalmic conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or disclosures by a company. The text includes a press release about the company's business update (advancement of a product candidate and strategic expansion) furnished as an exhibit. There are no financial statements or detailed financial data included in the text. The document is relatively short (3611 characters) and primarily serves as a regulatory announcement of a business development event. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a certification or officer attestation. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2021-07-22 English
FORM 4
Director's Dealing
2021-06-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 2, 2021, reporting the results of the 2021 Annual Meeting of Stockholders of Annexon, Inc. It details the voting results for director elections and ratification of the independent auditor. The content is focused on the submission of matters to a vote and the official voting outcomes. The document length is 3599 characters, which is relatively short and consistent with a voting results announcement rather than a full report. The key section is 'Item 5.07. Submission of Matters to a Vote of Security Holders,' which matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). Therefore, the appropriate classification is DVA with high confidence.
2021-06-08 English
FORM 4
Director's Dealing
2021-06-07 English
FORM 4
Director's Dealing
2021-06-04 English
FORM 4
Director's Dealing
2021-06-04 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.